Silverback Therapeutics (NASDAQ:SBTX) Shares Down 2.9% - Here's What Happened

Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shares traded down 2.9% during trading on Tuesday . The company traded as low as $10.01 and last traded at $10.18. 1,583,092 shares were traded during trading, an increase of 368% from the average session volume of 337,931 shares. The stock had previously closed at $10.48.Silverback Therapeutics Stock PerformanceThe stock has a market capitalization of $367.07 million, a P/E ratio of -4.21 and a beta of 0.60. The stock has a 50 day moving average of $11.93 and a 200 day moving average of $13.10. Silverback Therapeutics Company Profile (Get Free Report)Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.Featured ArticlesFive stocks we like better than Silverback TherapeuticsWhy Special Dividends Can be a Delightful Surprise for Income InvestorsGitLab: Get In While It’s Down—Big Rebound AheadDo ETFs Pay Dividends? What You Need to KnowTesla Stock: Finding a Bottom May Take TimeHow to Plot Fibonacci Price Inflection Levels Duolingo: This Beaten-Down Stock Is About to Rally 38%This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Silverback Therapeutics Right Now?Before you consider Silverback Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here